Bondinell W E, Chapin F W, Girard G R, Kaiser C, Krog A J, Pavloff A M, Schwartz M S, Silvestri J S, Vaidya P D, Lam B L, Wellman G R, Pendleton R G
J Med Chem. 1980 May;23(5):506-11. doi: 10.1021/jm00179a007.
In a search for inhibitors of epinephrine biosynthesis as potential therapeutic agents, a series of 13 ring-chlorinated 1,2,3,4-tetrahydroisoquinolines was prepared. These compounds were tested initially for their ability to inhibit rabbit adrenal phenylethanolamine N-methyltransferase (PNMT) in vitro. Enzyme-inhibitor dissociation constants, determined for the six most potent members of the series, indicated the following order of decreasing potency: 7,8-Cl2 greater than 6,7,8-Cl3 greater than 7-Cl approximately 5,6,7,8-Cl4 greater than 5,7,8-Cl3. These compounds were subsequently examined for PNMT-inhibiting activity in intact rats and mice. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline (13, SK&F 64139) was the most potent member of the series both in vitro and in vivo and is currently undergoing clinical investigation.
为了寻找作为潜在治疗药物的肾上腺素生物合成抑制剂,制备了一系列13种环氯化的1,2,3,4 - 四氢异喹啉。这些化合物最初在体外测试了它们抑制兔肾上腺苯乙醇胺N - 甲基转移酶(PNMT)的能力。针对该系列中六种最有效的成员测定的酶 - 抑制剂解离常数表明了以下效价递减顺序:7,8 - Cl₂大于6,7,8 - Cl₃大于7 - Cl约等于5,6,7,8 - Cl₄大于5,7,8 - Cl₃。随后在完整的大鼠和小鼠中检查了这些化合物的PNMT抑制活性。7,8 - 二氯 - 1,2,3,4 - 四氢异喹啉(13,SK&F 64139)是该系列在体外和体内最有效的成员,目前正在进行临床研究。